Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study

Transfusion

Volumn 49, Issue 5, 2009, Pages 977-984

  Dorsey, Kerri ^a   Zou, Shimian ^b   Schonberger, Lawrence B ^b   Sullivan, Marian ^b   Kessler, Debra ^b   Notari IV, Edward ^b   Fang, Chyang T ^b   Dodd, Roger Y ^b  

^a HOLLAND LABORATORY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; HEALTH SURVEY; HUMAN; MEDICAL RECORD; SURVIVAL RATE; UNITED STATES;

EID: 65349173916     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.02056.x     Document Type: Article

References (24)

1. Prusiner SB. Novel proteinaceous infectious particles causes scrapie. Science 1982 216 : 136 44.
2. Gambetti P, Kong Q, Zou W, Parchi P, Chen S. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003 66 : 213 39.
3. Belay ED, Schonberger LB. The public health impact of prion diseases. Annu Rev Public Health 2005 26 : 191 212.
4. Centers for Disease Control and Prevention (CDC). Surveillance for Creutzfeldt-Jakob disease - United States. MMWR Morb Mortal Wkly Rep 1996 45 : 665 8.
5. Centers for Disease Control and Prevention. CJD (Creutzfeldt-Jakob disease, classic). Atlanta (GA) : Centers for Disease Control and Prevention 2008 cited 2008 Apr 8. Retrieved from: http://www.cdc.gov/ncidod/dvrd/cjd/
6. Food and Drug Administration: Center for Biologics Evaluation and Research (CBER). Guidance for industry-revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products PDF file Rockville (MD) : U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) 2002 cited 2008 Jan 22. Retrieved from: http://www.fda.gov/cber/gdlns/cjdvcjd.pdf
7. Hewitt PE, Llewelyn CA, Mackenzie RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study (TMER). Vox Sang 2006 91 : 221 30.
8. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008 22 : 58 69.
9. Huillard d'Aignaux J, Costagliola D, Maccario J, Billette de Villemeur T, Brandel JP, Deslys JP, Hauw JJ, Chaussain JL, Agid Y, Dormont D, Alperovitch A. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999 53 : 1197 201.
10. Preusser M, Strobel T, Gelpi E, Eiler M, Broessner G, Schmutzhard E, Budka H. Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting. J Neurol Neurosurg Psychiatry 2006 77 : 413 6.
11. The National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU). CJD statistics. Edinburgh : NCJDSU 2008 cited 2008 Apr 24. Retrieved from: http://www.cjd.ed.ac.uk/figures.htm
12. National Prion Disease Pathology Surveillance Center. National prion disease pathology surveillance center: cases examined. Cleveland (OH) : National Prion Disease Pathology Surveillance Center 2007 cited 2008 Apr 24. Retrieved from: http://www.cjdsurveillance.com/pdf/case-table.pdf
13. Brown P. Pathogensis and transfusion risk of transmissible spongiform encephalopathies. Dev Biol Adv Transfus Saf 2005 120 : 27 33.
14. Heye N, Hensen S, Müller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet (Comment) 1994 343 : 298 9.
15. Wilson K, Code C, Ricketts M. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusion:systematic review of case-control studies. Br J Med 2000 231 : 17 9.
16. Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998 38 : 817 20.
17. Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998 80 : 909 11.
18. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. J Gen Virol 2002 83 : 2897 905.
19. Cervenakova L, Yakovlena O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003 43 : 1687 94.
20. Davanipour Z, Smoak C, Bohr T, Sobel E, Liwnicz B, Chang S. Death certificates: an efficient source of ascertainment of Creutzfeldt-Jakob disease cases. Neuroepidemiology 1995 14 : 1 6.
21. Dorsey KA, Zou S, Notari E IV., Fang C, Schonberger L. Survival Analysis of Blood Transfusion Recipients. The 135th Annual Meeting & Exposition of the American Public Health Association (APHA), November 3-7, 2007, Washington, DC. Abstract no. 157850. cited 2008 Dec 10. Retrieved from: http://apha.confex. com/apha/135am/techprogram/paper-157850.htm
22. Vamvakas EC. Ten-year survival of transfusion recipients identified by hepatitis C lookback. Transfusion 2003 43 : 418.
23. Vamvakas EC. Uses and sources of data on long-term survival after blood transfusion. Transfus Med Rev 2003 17 : 194 208.
24. Herzog C, Riviere J, Lescoutra-Etchegaray N, Charbonnier A, Leblanc V, Salès N, Deslys JP, Lasmézas CI. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol 2005 79 : 14339 45.